Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

152.55 +0.28 (+0.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 381,506
Open 152.50
Bid (Size) 138.00 (1)
Ask (Size) 154.80 (1)
Prev. Close 152.27
Today's Range 150.20 - 152.68
52wk Range 103.63 - 157.98
Shares Outstanding 100,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) suited for quality investing? 
Via Chartmill

Performance

YTD
+15.81%
+15.81%
1 Month
+5.03%
+5.03%
3 Month
+8.59%
+8.59%
6 Month
+12.14%
+12.14%
1 Year
+42.73%
+42.73%

More News

Read More
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
Via Benzinga
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
Via Chartmill
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences
Via Benzinga
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
Via Chartmill
NASDAQ:NBIX, a growth stock which is not overvalued.
Via Chartmill
New Study Reveals How Classical Music Could Revolutionize Depression Care
Via PressReach
Exposures Product Safety
So Much For Expecting The Fed To Stick The Landing
Via Talk Markets
Topics Economy
Exposures Interest Rates
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Should Quality Investors Include NASDAQ:NBIX in Their Portfolio?
Via Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Via Benzinga
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
Via Chartmill
Reasonable Growth, Debt Levels, and a High ROIC Make NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Appealing to Quality Investors.
Via Chartmill
Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued.
Via Chartmill
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Key Takeaways From Neurocrine Biosciences Analyst Ratings
Via Benzinga
Exploring NASDAQ:NBIX's quality characteristics.
Via Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
Via Chartmill
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Via Investor's Business Daily
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.